Phlexglobal, a technology and services provider for the life sciences industry, announced the general availability of the industry’s first and only complete TMF management offering from a single expert provider. The company’s new PhlexTMF+ provides a one-stop, full-service solution that encompasses all the software and services required for effective TMF management and ongoing inspection-readiness. Organizations can be confident that their Trial Master File is being managed by experts every step of the way, from planning and document processing and study closeout.
With PhlexTMF+, life sciences organizations now have ready access to the latest advances in eTMF SaaS software, the world’s leading TMF experts, and best practices-based processes proven to optimize TMF quality, completeness, and timeliness – from a single provider and in one seamless offering. Companies gain ongoing TMF compliance, as well as the freedom to shift study resources from time-consuming TMF management to other critical objectives, reducing the risk of inspection findings and submission delays.
“You can think of PhlexTMF+ as ‘TMF management as a service,’” observes Karen Roy, Phlexglobal’s Chief Strategy Officer and Chair, TMF Reference Model. “By delivering everything critical to Trial Master File health, including purpose-built SaaS eTMF software, workflows, and expert guidance, we remove the burden of TMF compliance from our customers.”
Building on Phlexglobal’s decades of industry leadership in Trial Master File technology and best practices, the innovative new solution standardizes end-to-end TMF management to ensure consistent, accurate, and current compliance throughout the TMF lifecycle. What’s more, PhlexTMF+ fits each organization’s unique requirements, providing agile, fit-for-purpose TMF management – eliminating paying for software and services that don’t support TMF health.
Key benefits of PhlexTMF+ include:
“PhlexTMF+ is further evidence of Phlexglobal’s authoritative position helping life sciences companies worldwide stay compliant with ever-shifting regulatory mandates,” said John McNeill, Chief Executive Officer of Phlexglobal. “We’ve transformed a traditionally siloed and challenging TMF management process into a seamless, expert solution from a single source, providing our customers with even greater compliance peace of mind.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.